| Course | D027 Advanced Pathopharmacological Foundations |
|---|---|
| Task | Task 1 |
| Paper type | Pathophysiology and treatment synthesis |
| Length | About 800 words, 4 pages |
| Format | APA 7 |
| School | Western Governors University (WGU) |
| Program | MSN |
| Updated | September 2026 |
Free sample paper for D027 Task 1
Pathophysiology and Treatment Synthesis: Acute Pulmonary Embolism in a 58-Year-Old Woman After a Long Car Journey
Student Name
Leavitt School of Health, Western Governors University
D027: Advanced Pathopharmacological Foundations, Task 1
Course Instructor
Month Day, Year
Pathophysiology and Treatment Synthesis: Acute Pulmonary Embolism in a 58-Year-Old Woman After a Long Car Journey
Patient Summary
The composite patient is a 58-year-old woman who presents to the emergency department with sudden shortness of breath and sharp right-sided chest pain that worsens with deep breaths, beginning three hours after she finished a nine-hour car journey. She takes an estrogen-containing hormone therapy for menopausal symptoms and had right ankle surgery five weeks ago. Findings: heart rate 112, respirations 24 per minute, blood pressure 128/78, saturation 91% breathing room air, temperature 37.6 C, and a swollen, tender right calf. The D-dimer is elevated, troponin is mildly raised, and computed tomography pulmonary angiography shows emboli in the right lower lobe and segmental arteries of the right middle lobe, with a right ventricle to left ventricle ratio of 1.1 on imaging.
Pathophysiology
Pulmonary embolism occurs when a thrombus, usually formed in a deep vein of the leg, breaks loose and lodges in the pulmonary arteries (Freund et al., 2022). This patient shows all three parts of Virchow's triad: venous stasis from a long period of sitting and reduced mobility after surgery, endothelial injury from the recent operation, and hypercoagulability from estrogen therapy. A clot formed in the right calf veins, the source of her swollen, tender leg, and traveled through the right heart into the pulmonary circulation.
Once lodged, the embolus blocks blood flow to part of the lung. Those lung units are still ventilated but no longer perfused, creating dead space, while blood diverted to the remaining vessels overwhelms their capacity and creates areas of low ventilation relative to perfusion. The result is hypoxemia, which explains her saturation of 91%, and a rapid breathing rate as she tries to compensate. Pleuritic chest pain and a low-grade fever reflect inflammation and small areas of infarction at the lung's edge.
The obstruction also raises pressure in the pulmonary arteries. The right ventricle, a thin-walled chamber built for low pressure, must pump against this sudden load, and it dilates and strains. Chemicals released from platelets in the clot, including serotonin and thromboxane, add to the vasoconstriction. Right ventricular strain explains her enlarged right ventricle on imaging and her raised troponin, which signals myocardial injury. Her tachycardia is the heart's attempt to maintain output. If the right ventricle fails, output to the left heart falls and blood pressure drops; her pressure is still normal, which places her in an intermediate-risk group rather than the high-risk group with shock (Konstantinides et al., 2020).
Pharmacological Treatment
Anticoagulation is the foundation of treatment. It does not dissolve the existing clot; it stops the clot from growing and prevents new clots while the body's own fibrinolytic system gradually breaks the embolus down. Because she is intermediate risk, she starts on low-molecular-weight heparin, enoxaparin 1 mg/kg subcutaneously every 12 hours, which enhances antithrombin's inhibition of factor Xa, and is monitored for signs of deterioration during the first days. When stable, she will switch to a direct oral anticoagulant such as apixaban, which inhibits factor Xa directly. Compared with heparin followed by warfarin, direct oral anticoagulants are noninferior for treating pulmonary embolism and carry a lower rate of bleeding (Freund et al., 2022). Treatment will continue for three months, the recommended primary treatment phase, because the embolism was provoked by temporary risk factors, and the need for longer therapy will be reviewed at that point (Stevens et al., 2021).
Systemic thrombolysis with alteplase, which converts plasminogen to plasmin and dissolves fibrin, is reserved for patients whose blood pressure falls below 90 mm Hg or who deteriorate despite anticoagulation, because it carries a meaningful risk of major bleeding, including intracranial hemorrhage (Konstantinides et al., 2020). Supplemental oxygen corrects her hypoxemia, and acetaminophen treats pleuritic pain; nonsteroidal anti-inflammatory drugs are avoided because they add to bleeding risk with anticoagulation.
Non-Pharmacological Treatment
Her estrogen therapy should be stopped, since it contributed to her clotting risk, and the prescriber will discuss non-hormonal options for menopausal symptoms. Early mobilization once she is stable is encouraged rather than bed rest, which adds to venous stasis. Graduated compression stockings may help leg swelling and comfort. An inferior vena cava filter is considered only if anticoagulation becomes impossible because of bleeding, since it does not treat the clot and can itself cause thrombosis.
Teaching Points
The patient needs to take her anticoagulant exactly as prescribed, without missed doses, and to recognize signs of bleeding, such as black stools, blood in urine or unusual bruising, and signs of a new clot, such as new leg swelling or worsening breathlessness. On future long journeys she should stop to walk every one to two hours and stay hydrated. She should tell every clinician and dentist that she takes an anticoagulant, and avoid over-the-counter pain relievers that increase bleeding without checking first.
References
Freund, Y., Cohen-Aubart, F., & Bloom, B. (2022). Acute pulmonary embolism: A review. JAMA, 328(13), 1336-1345. https://doi.org/10.1001/jama.2022.16815
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., Kucher, N., Lang, I. M., Lankeit, M., Lorusso, R., Mazzolai, L., Meneveau, N., Ní Áinle, F., Prandoni, P., Pruszczyk, P., . . . Pepke-Zaba, J. (2020). 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal, 41(4), 543-603. https://doi.org/10.1093/eurheartj/ehz405
Stevens, S. M., Woller, S. C., Kreuziger, L. B., Bounameaux, H., Doerschug, K., Geersing, G.-J., Huisman, M. V., Kearon, C., King, C. S., Knighton, A. J., Lake, E., Murin, S., Vintch, J. R., Wells, P. S., & Moores, L. K. (2021). Antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report. Chest, 160(6), e545-e608. https://doi.org/10.1016/j.chest.2021.07.055
What the D027 Task 1 instructions ask
The first D027 task asks for a concise synthesis that links pathophysiology to pharmacological and non-pharmacological treatment for a specific condition in a specific patient. Most versions ask you to summarize the patient, explain the disease mechanism, describe drug treatment with how each drug acts on that mechanism, describe non-drug treatment and include teaching points. The synthesis is often limited in length, so every sentence has to earn its place. Evidence should come from current guidelines and reviews. The evaluator reads for a clear chain from cause to mechanism to treatment, with drugs explained by what they do in the body rather than listed by name and dose alone. Some versions also ask for a short list of references in APA style.
How this D027 Task 1 example is built
The synthesis opens with a short patient summary that includes the risk factors the mechanism will later explain, such as prolonged sitting and estrogen therapy. The pathophysiology section follows the clot from its origin to its effect on the pulmonary circulation and the right ventricle, using Virchow's triad implicitly through the patient's risks. The pharmacological section explains what anticoagulation does and does not do, which prevents a common misunderstanding about dissolving clots. Non-pharmacological treatment addresses the modifiable risk and early recovery. Teaching points are written in plain language a patient could follow. Current European guidance and a clinical review support each section, and the length stays within the one-page style the task expects.
Where the D027 Task 1 rubric puts the marks
D027 Task 1 is scored aspect by aspect at competent, approaching competence or not evident. A patient summary aspect checks that the presentation is described with relevant findings. A pathophysiology aspect wants an accurate mechanism linked to this patient. A pharmacological aspect looks for drugs explained by mechanism of action and connected to the pathophysiology. A non-pharmacological aspect asks for relevant supportive measures. A teaching aspect looks for accurate, patient-centered points. Evaluators reward precision and economy, and they check that sources are current and cited in APA style. Clinical inaccuracies, such as claiming anticoagulants dissolve clots, can hold back an otherwise solid synthesis. Syntheses that stay within the expected length while covering every element tend to impress evaluators more than longer ones that wander.
D027 Task 1 help: what sends it back
The most common problem in D027 Task 1 is a treatment list disconnected from the mechanism. For each drug, say what it does to the process you described. Second, pathophysiology is copied from a textbook in general terms. Tie each step to the patient's risks and findings. Third, students exceed the length limit trying to include everything. Choose the points that matter for this patient. Fourth, teaching points are written for clinicians. Rewrite them in words a patient would use. Finally, check facts against a current guideline, since recommendations for anticoagulant choice and duration change, and an outdated recommendation is an easy error for an evaluator to spot.
Get a D027 Task 1 example written to your instructions
Send the D027 portfolio instructions from your course of study and the condition you need to synthesize. We write a custom synthesis to those exact requirements and return it in 24-48h. The first custom sample is free.
More D027 papers
Other Nursing (MSN) sample papers
- D156 Task 1 Practice Problem Analysis
- C855 Task 1 System Optimization Proposal
- D155 Task 2 Personal Mastery Reflection
- D031 Task 2 Sample Paper
D027 Task 1 questions, answered
Is D027 an exam or a paper?
In current versions both: the course has a proctored objective assessment and a clinical practice experience portfolio. This library covers the written portfolio pieces only. Exams are sat under supervision and are yours alone, and so are logs, recordings and feedback from colleagues.
How long should the D027 synthesis be?
Your instructions set the length, and many versions ask for about a page. Keep it dense: every sentence should explain a mechanism, a finding or a treatment choice. A longer draft can be cut down once the links are clear.
What should the D027 synthesis connect?
The pathophysiology to the patient's findings, and the pathophysiology to each treatment. If a colleague can see why the patient has each symptom and why each drug or intervention helps, the synthesis is doing its job.
What should a D027 synthesis connect?
The patient's risk factors to the disease mechanism, and the mechanism to each treatment. The sample links a long car journey and estrogen to clot formation and explains how anticoagulation interrupts clot growth.
Where can I find a free D027 Task 1 sample paper?
The complete pulmonary embolism synthesis is reproduced above with margin notes. Tell us the condition and send the D027 instructions; your first tailored synthesis costs nothing.